Risk of heart failure in elderly patients with atrial fibrillation and diabetes taking different oral anticoagulants: a nationwide cohort study

Table 3 Risk of heart failure in older patients with atrial fibrillation and diabetes receiving each NOAC versus warfarin

	Fine stratification weights estimating ATE^*		Fine stratification weights estimating ATT^**
	HR^† (95% CI)	p-value	HR^† (95% CI)	p-value
Dabigatran vs. warfarin	0.86 (0.80–0.93)	< 0.001	0.81 (0.75–0.88)	< 0.001
Rivaroxaban vs. warfarin	0.80 (0.74–0.86)	< 0.001	0.77 (0.71–0.83)	< 0.001
Apixaban vs. warfarin	0.78 (0.68–0.90)	< 0.001	0.72 (0.62–0.83)	< 0.001
Edoxaban vs. warfarin	0.72 (0.60–0.86)	< 0.001	0.66 (0.54–0.81)	< 0.001

ATE average treatment effect in the whole population, ATT average treatment effect among the treated population, CI confidence interval, HR hazard ratio
^*Propensity score-based fine stratification weighting which estimated the average treatment effect in the whole population
^**Propensity score-based fine stratification weighting which estimated the average treatment effect among the treated population
^†The HR is calculated using patients taking warfarin as the reference group

ISSN: 1475-2840